After six years, a breast cancer drug cut the risk of death by 19% — earlier than doctors expected

Doctors expected it might take ten years to know whether Novartis's Kisqali truly helps women with high-risk early breast cancer live longer. At six years, the answer is already coming in: women who received Kisqali with hormone therapy had a 19% lower risk of death, with 91.9% alive compared with 89.7% on hormone therapy alone, in data presented at the European Society for Medical Oncology congress in Madrid. Lead investigator Dennis Slamon of UCLA said the gap is widening sooner than expected.

SDG 3 · Good health and well-being — Mechanism: tech innovation